Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) COO Patrick John Finn sold 2,174 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the transaction, the chief operating officer now owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Patrick John Finn also recently made the following trade(s):
- On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total value of $16,108.08.
Twist Bioscience Trading Up 1.1 %
TWST stock opened at $31.08 on Friday. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21. The stock’s fifty day moving average is $34.97 and its two-hundred day moving average is $30.32.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on TWST. Scotiabank raised their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th.
View Our Latest Stock Analysis on Twist Bioscience
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of TWST. Artisan Partners Limited Partnership increased its holdings in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares during the period. Invesco Ltd. increased its holdings in shares of Twist Bioscience by 1,496.2% during the third quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after purchasing an additional 778,944 shares during the period. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares during the period. AEGON ASSET MANAGEMENT UK Plc acquired a new position in Twist Bioscience during the fourth quarter worth about $11,956,000. Finally, Norges Bank acquired a new position in Twist Bioscience during the fourth quarter worth about $10,766,000.
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
- Five stocks we like better than Twist Bioscience
- How to Effectively Use the MarketBeat Ratings Screener
- Hasbro’s Management Made All the Right Calls This Quarter
- Trading Halts Explained
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Calculate Options Profits
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.